for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Enzyvant receives FDA breakthrough therapy designation for investigational therapy rvt-802

April 17 (Reuters) -

* Enzyvant receives FDA breakthrough therapy designation and regenerative medicine advanced therapy designation for investigational therapy rvt-802

* Enzyvant says receives U.S FDA breakthrough therapy designation and regenerative medicine advanced therapy designation for its rvt-802

* Enzyvant says it anticipates potential bla filing in first half of 2018 Source text for Eikon:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up